Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited

Laiba Immad

Wed, February 18, 2026 at 2:54 PM GMT+9 2 min read

In this article:

ARWR

-0.20%

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited

The tenth stock on our list is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR).

TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating. The firm noted that the company stated that it is still moving forward with its pipeline and that several significant readouts, such as Phase 3 data for SHTG in Q3, are anticipated later this year. The firm anticipates that significant sales from this program will not materialize in 2026, despite the promising early launch trends for the familial chylomicronemia syndrome treatment.

Additionally, on January 27, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that it has dosed the first participants in its Phase 1/2a clinical trial of ARO-DIMER-PA. This is an investigational RNAi therapy that may be used to treat atherosclerotic cardiovascular disease caused by mixed hyperlipidemia. The goal of the dual-targeted medication ARO-DIMER-PA is to simultaneously suppress the genes APOC3 (apolipoprotein C3) and PCSK9 (proprotein convertase subtilisin/kexin type 9). By concentrating on both pathways, the treatment aims to more effectively reduce lipid levels, which tends to offer a novel approach for cardiovascular risk patients with elevated cholesterol and triglycerides.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a U.S. biotech innovator developing RNA interference (RNAi) medicines that silence disease‑causing genes. Its proprietary TRiM RNAi platform enables targeted, durable therapies for previously “undruggable” conditions and advances treatments across cardiometabolic, rare genetic, and other diseases.

While we acknowledge the potential of ARWR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.

Terms and Privacy Policy

Privacy Dashboard

More Info